Monitoring a national cancer prevention program: Successful changes in cervical cancer screening in the Netherlands

International Journal of Cancer

Volumn 120, Issue 4, 2007, Pages 806-812

  Rebolj, Matejka ^a   Van Ballegooijen, Marjolein ^a   Berkers, Louise Maria ^a   Habbema, Dik ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cervical cancer; Coverage; Follow up; Mass screening; The Netherlands

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER PREVENTION; CANCER SCREENING; CLINICAL PROTOCOL; EVIDENCE BASED PRACTICE; FEMALE; FOLLOW UP; HEALTH CARE FINANCING; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; NATIONAL HEALTH SERVICE; NETHERLANDS; PAPANICOLAOU TEST; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE ENDOCERVIX;

ADULT; CERVIX UTERI; CYTODIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HEALTH PLAN IMPLEMENTATION; HUMANS; MASS SCREENING; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; NETHERLANDS; PRACTICE GUIDELINES; PRECANCEROUS CONDITIONS; PROGRAM EVALUATION; REFERRAL AND CONSULTATION; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 33846643040     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22167     Document Type: Article

References (56)

1. The Council of the European Union. Council recommendation of 2 December 2003 on cancer screening. Off J Eur Union 2003;46:34-8.
2. Shapiro S, Coleman EA, Broeders M, Codd M, de Koning H, Fracheboud J, Moss S, Paci E, Stachenko S, Ballard-Barbash R. Breast cancer screening programmes in 22 countries: current policies, administration and guidelines. International Breast Cancer Screening Network (IBSN) and the European Network of Pilot Projects for Breast Cancer Screening. Int J Epidemiol 1998;27:735-42.
3. Anttila A, Ronco G, Clifford G, Bray F, Hakama M, Arbyn M, Weiderpass E. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004;91:935-41.
4. UK Colorectal Cancer Screening Pilot Group. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. Br Med J 2004;329:133-5.
5. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000;21:273S-309S.
6. Mulshine JL, Sullivan DC. Clinical practice. Lung cancer screening. N Engl J Med 2005;352:2714-20.
7. Koning HJd, Auvinen A, Berenguer Sanchez A, Calais da Silva F, Ciatto S, Denis L, Gohagan JK, Hakama M, Hugosson J, Kranse R, Nelen V, Prorok PC, et al. Large-scale randomized prostate cancer screening trials: program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 2002;97:237-44.
8. Koning HJd, Coebergh JW, van Dongen JA. Is mass screening for breast cancer cost-effective? Eur J Cancer 1996;32A:1835-44.
9. Wardle J, Pope R. The psychological costs of screening for cancer. J Psychosom Res 1992;36:609-24.
10. Hewitt M, Devesa SS, Breen N. Cervical cancer screening among U.S. women: analyses of the 2000 National Health Interview Survey. Prev Med 2004;39:270-8.
11. Spence MT, Woodman C, Collins S, Donnelly B, Desai M. Cervical smears-an opportunity for disinvestment? Br J Gen Pract 1996;46:537, 538.
12. Rappaport KM, Forrest CB, Holtzman NA. Adoption of liquid-based cervical cancer screening tests by family physicians and gynecologists. Health Serv Res 2004;39:927-47.
13. Chamberlain J. Failures of the cervical cytology screening programme. Br Med J (Clin Res Ed) 1984;289:853, 854.
14. Day NE. Screening for cancer of the cervix. J Epidemiol Community Health 1989;43:103-6.
15. Anonymous. Cancer of the cervix: death by incompetence. Lancet 1985;2:363, 364.
16. Giard RW, Hermans J, Doornewaard H. National results of cervix cytology diagnosis in 1992; efficacy of screenine could be improved (in Dutch). Ned Tijdschr Geneeskd 1994;138:1325-30.
17. Elven EHv, Griffioen HP, Wiegman HP. Survey into bottlenecks of the organised cervical cancer screening programme (in Dutch). KPMG, Amstelveen, The Netherlands, 1990.
18. van Ballegooijen M, Boer R, van Oortmarssen GJ, Koopmanschap MA, Lubbe JTN, Habbema JDF. Cervical cancer screening programme: age ranges and intervals. An updated cost-effectiveness analysis (in Dutch). Department of Public Health, Erasmus University Rotterdam, Rotterdam, The Netherlands, 1993.
19. van Ballegooijen M, Habbema JD, van Oortmarssen GJ, Koopmanschap MA, Lubbe JT, van Agt HM. Preventive Pap-smears: balancing costs, risks and benefits. Br J Cancer 1992;65:930-3.
20. Simons HJ. Organised cervical cancer screening programme (in Dutch). Rijswijk, The Netherlands, 1991. [Letter of the Ministry of Welfare. Public Health and Cultural Affairs, 18 April 1991 (PEP/GZ 001027)].
21. National Health Insurance Council. Starting points for the restructuring of the organised cervical cancer screening programme-Final decision (in Dutch). ZiekenfondsRaad, Amstelveen, The Netherlands, 1993.
22. Hermens RP, Hak E, Hulscher ME, Braspenning JC, Grol RP. Adherence to guidelines on cervical cancer screening in general practice: programme elements of successful implementation. Br J Gen Pract 2001;51:897-903.
23. Fahs MC, Plichta SB, Mandelblatt JS. Cost-effective policies for cervical cancer screening. An international review. Pharmacoeconomics 1996;9:211-30.
24. Dutch Association of Pathologists. CISOE-A in pictures (in Dutch). CD-Rom. In: Hanselaar AGJM, ed. Nijmegen, The Netherlands: University Medical center Nijmegen, 1997.
25. Hanselaar AG, Heimerhorst TJ, van der Veer P, Drenthen T. A repeat advice no longer applies for cervical smears without endocervical cells in population studies for cervical cancer (in Dutch). Ned Tijdschr Geneeskd 2002;146:1578-80.
26. Bos AB, van Ballegooijen M, Elske van den Akker-van Marie M, Hanselaar AG, van Oortmarssen GJ, Habbema JD. Endocervical status is not predictive of the incidence of cervical cancer in the years after negative smears. Am J Clin Pathol 2001;115:851-5.
27. PALGA. Description of the PALGA system and computer network (in Dutch). Utrecht, The Netherlands, 2004. Available at http://www.palga.nl.
28. van den Brandt PA, Schouten LJ, Goldbohm RA, Dorant E, Hunen PM. Development of a record linkage protocol for use in the Dutch Cancer Registry for epidemiological research. Int J Epidemiol 1990;19:553-8.
29. van den Akker-van Marie M, van Ballegooijen M, Habbema JD. Low risk of cervical cancer during a long period after negative screening in the Netherlands. Br J Cancer 2003;88:1054-7.
30. Central Bureau of Statistics. Population: age, sex, marital status per January 1st (in Dutch). Centraal Bureau voor de Statistiek, Voorburg/Heerlen, The Netherlands, 2005. Available at http://statline.cbs.nl.
31. Prismant. LMR data on hospital admissions 1975-2000. Utrecht, The Netherlands, 2003.
32. Koopmanschap MA, van Oortmarssen GJ, van Agt HM, van Ballegooijen M, Habbema JD, Lubbe JT. Cervical-cancer screening: attendance and cost-effectiveness. Int J Cancer 1990;45:410-5.
33. Sherlaw-Johnson C, Gallivan S, Jenkins D, Jones MH. Cytological screening and management of abnormalities in prevention of cervical cancer: an overview with stochastic modelling. J Clin Pathol 1994;47:430-5.
34. Hermens RP, Tacken MA, Hulscher ME, Braspenning JC, Grol RP. Attendance to cervical cancer screening in family practices in The Netherlands. Prev Med 2000;30:35-42.
35. Patnick J. Cervical cancer screening in England. Eur J Cancer 2000;36:2205-8.
36. Emerson RE, Puzanov A, Brunnemer C, Younger C, Cramer H. Long-term follow-up of women with atypical squamous cells of undetermined significance (ASCUS). Diagn Cytopathol 2002;27:153-7.
37. Nygard JF, Sauer T, Skjeldestad FE, Skare GB, Thoresen SO. CIN 2/3 and cervical cancer after an ASCUS pap smear. A 7-year, prospective study of the Norwegian population-based, coordinated screening program. Acta Cytol 2003;47:991-1000.
38. van Oortmarssen GJ, Habbema JD. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer 1991;64:559-65.
39. Bos AB, van Ballegooijen M, van Oortmarssen GJ, van Marie ME, Habbema JD, Lynge E. Non-progression of cervical intraepithelial neoplasia estimated from population-screening data. Br J Cancer 1997;75:124-30.
40. Plaxe SC, Saltzstein SL. Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. Gynecol Oncol 1999;75:55-61.
41. Linos A, Riza E. Comparisons of cervical cancer screening programmes in the European Union. Eur J Cancer 2000;36:2260-5.
42. van Ballegooijen M, van den Akker-van Marie E, Patnick J, Lynge E, Arbyn M, Anttila A, Ronco G, Dik J, Habbema F. Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer 2000;36:2177-88.
43. World Health Organisation. WHO Statistical Information System-Mortality database. World Health Organisation, Geneva, 2004. Available at http://www.depdb.iarc.fr/who/menu.htm; Last updated: Dec 2004.
44. Anttila A, Nieminen P. Cervical cancer screening programme in Finland. Eur J Cancer 2000;36:2209-14.
45. Nieminen P, Hakama M, Viikki M, Tarkkanen J, Anttila A. Prospective and randomised public-health trial on neural network-assisted screening for cervical cancer in Finland: results of the first year. Int J Cancer 2003;103:422-6.
46. Cancer Registry Finland. Screening for cervical cancer in 2002. Available at http://www.cancerregistry.fi/v2002/v200200kohtu.html. (last updated 2005).
47. Department of Health. Cervical Screening Programme, England: 2003-04. Statistical Bulletin. Department of Health, London, 2004. Available at www.publications.doh.gov.uk/public/sb0420.pdf.
48. Dillner J. Cervical cancer screening in Sweden. Eur J Cancer 2000;36:2255-9.
49. Appelman CLM, Bruinsma M, Collette C, van Weel C, Geijer RMM. Standard of the Dutch College of GPs concerning cervical smears (1st revision, in Dutch). Huisarts Wet 1996;39:134-41.
50. National Institute for Clinical Excellence (NICE). Guidance on the use of liquid-based cytology for cervical screening. National Institute for Clinical Excellence, London, UK, 2003. Technology Appraisal 69.
51. Meerding WJ. Describing health and medical costs, and the economic evaluation of health care: applications in injuries and cervical cancer (Thesis). Department of Public Health Rotterdam, Erasmus MC, 2004.
52. Burgers JS, Grol RP, Zaat JO, Spies TH, van der Bij AK, Mokkink HG. Characteristics of effective clinical guidelines for general practice. Br J Gen Pract 2003;53:15-19.
53. Natsch S, van der Meer JW. The role of clinical guidelines, policies and stewardship. J Hosp Infect 2003;53:172-6.
54. Helmerhorst TJM, Wijnen JA. Guidelines on organised cervical cancer screening programme (in Dutch). Ned Tijdschr Obstet Gynaecol 1998;111:264,265.
55. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet 2003;362:1225-30.
56. van Ballegooijen M, Bouwman-Notenboom AJ, van den Akker-van Marie EM, Bos AB, van Oortmarssen GJ, Boer R, Meerding WJ, Stolk WA, Habbema F. Organised cervical cancer screening programme practice in the Netherlands in 1996 and 1997 (in Dutch). Department of Public Health, Erasmus University, Rotterdam, The Netherlands, 2000.